Opioid antagonist naloxone considered safe for over-the-counter use
The US FDA have approved the distribution of naloxone, a drug that reverses opioid overdose, in an over-the-counter setting, in some dosage forms.
The opioid crisis was declared a public health emergency in the US in 2017. Since then, pharmaceutical companies have been working on solutions to ease the epidemic.
In some states across the US opioid overdose is the leading cause of death in adults ages 18–44 years.
Naloxone, an opioid antagonist, is used to reverse opioid overdose. It works by attaching to opioid receptors and blocking other opioids, reversing the effects.
It can be administered as a nasal spray or injected into the muscle, skin or veins, and is effective in reversing opioid overdoses in all dosage forms.
The US FDA have now confirmed that naloxone is safe and effective for over-the-counter use, in certain approved forms of administration.
The regulations cover a dose of up to 4 mg of a naloxone nasal spray and a dose of 2 mg via an auto injector, after initial assessments.
The FDA is still gathering data on individual products from various manufacturers to establish whether they can also be available for over-the-counter use. They have yet to see whether these products, which supply the drug in different forms, will be considered safe in this setting, as well as examining higher dosage forms.
Currently, doctors can prescribe naloxone as a life-saving antidote to opioid overdose, if administered quickly to patients prescribed high-dose opioids. Some states in the US allow the use of the drug without prescription, or through official community programmes.
In 2020, over 16,000 people died from overdoses involving just prescription opioids, this figure has increased year on year.
By making the opioid antagonist more accessible to at-risk patients, the number of deaths due to overdose will hopefully start to decrease.
Related News
-
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News Roche breaks into the obesity drug market with the acquisition of Carmot Therapeutics
In a bid to diversify their therapeutic offerings, Roche takes over Carmot Therapeutics in $2.7 billion deal, with one obesity drug spearheading the venture into the field as they prep for a Phase II in-human trial. -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News Women in Pharma: Delivering solutions for gender diversity
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona Speaker Interview – What the US FDA’s Quality Management Maturity Means for the Pharma Industry
At CPHI Barcelona (24–26 October, 2023), we spoke to Sireesha Yadlapalli, CEO of Pharmatech Associates, who gave a presentation on the implications of the US FDA’s Quality Management Maturity (QMM) Initiative, and spoke on the panel of the ... -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Wegovy and weight-loss drugs driving demand for manufacturers that can fill syringes
Injectable weight-loss treatments are prompting contract manufacturers to invest and include fill-finish services into their service portfolios, in a bid to attract pharmaceutical giants developing drugs similar to Novo Nordisk's Wegovy.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance